Screener
Regeneron Pharmaceuticals REGN Deferred Revenue
Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Regeneron Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityCurrent.
The source filing: Regeneron Pharmaceuticals’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 6:52 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000872589-26-000025
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Accounts payable | $1,159.3 | $939.0 |
| Accrued expenses and other current liabilities | 2,966.5 | 2,876.4 |
| Finance lease liabilities | 720.0 | — |
| Deferred revenue | 684.8 | 553.0 |
| Total current liabilities | 5,530.6 | 4,368.4 |
| Long-term debt | 1,986.6 | 1,985.9 |
| Finance lease liabilities | — | 720.0 |
| Deferred revenue | 220.4 | 208.7 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Regeneron Pharmaceuticals's deferred revenue?
- Regeneron Pharmaceuticals (REGN) reported deferred revenue of $684.8M in Q2 2026.
- How has Regeneron Pharmaceuticals's deferred revenue changed year-over-year?
- Regeneron Pharmaceuticals's deferred revenue increased by 42.1% year-over-year, from $481.9M to $684.8M.
- What is the long-term trend for Regeneron Pharmaceuticals's deferred revenue?
- Over 5 years (2020 to 2025), Regeneron Pharmaceuticals's deferred revenue has grown at a -0.9% compound annual growth rate (CAGR), from $577.7M to $553M.
- What does deferred revenue mean?
- Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.
Ask your AI about Regeneron Pharmaceuticals's deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude